Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Equivalents: 2010-2025

Historic Revenue - Interest and Investment Income for Sunshine Biopharma (SBFM) over the last 1 years, with Dec 2010 value amounting to $207,624.

  • Sunshine Biopharma's Cash & Equivalents fell 23.76% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 23.76%. This contributed to the annual value of $9.7 million for FY2024, which is 40.55% down from last year.
  • Sunshine Biopharma's Cash & Equivalents amounted to $9.3 million in Q3 2025, which was down 9.69% from $10.3 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Cash & Equivalents peaked at $41.7 million during Q2 2022, and registered a low of $1.7 million during Q2 2021.
  • For the 3-year period, Sunshine Biopharma's Cash & Equivalents averaged around $13.9 million, with its median value being $12.2 million (2024).
  • As far as peak fluctuations go, Sunshine Biopharma's Cash & Equivalents surged by 16,522.83% in 2021, and later tumbled by 53.53% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Cash & Equivalents (MRQ) stood at $2.0 million in 2021, then skyrocketed by 967.22% to $21.8 million in 2022, then decreased by 25.35% to $16.3 million in 2023, then plummeted by 40.55% to $9.7 million in 2024, then fell by 3.92% to $9.3 million in 2025.
  • Its last three reported values are $207,624 in Q4 2010, $108,148 for Q3 2010, and $16,291 during Q2 2010.